MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Journal of Neuro-oncology
Yunxiang ChenXiefeng Wang

Abstract

Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM). However, resistance to TMZ develops quickly with a high frequency. The mechanisms underlying GBM cells' resistance to TMZ are not fully understood. MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate protein expression by cleaving or repressing the translation of target mRNAs. Recently, miRNAs have been discovered to play important roles in drug resistance. A previous study showed that miR-181b in involved in glioma tumorigenesis. Thus, it would be valuable to explore the functions and mechanisms of miR-181b in regulating GMB cells' sensitivity to TMZ. In this study, quantitative real-time reverse transcription PCR (qRT-PCR) data indicated that miR-181b was significantly downregulated in recurrent GBM tissues compared with initial GBM tissues. We also found that miR-181b overexpression increased the chemo-sensitivity of GBM cells to TMZ and potentiated TMZ-induced apoptosis in vitro and in vivo. Moreover, we demonstrated that the epidermal growth factor receptor (EGFR) was a direct target of miR-181b: restoration of EGFR rescued the inhibitory effects of miR-181b and TMZ treatment. Taken together, our data support s...Continue Reading

References

Nov 1, 1993·European Heart Journal·J M Detry
Jul 11, 2003·Lancet·Janet E Dancey, Boris Freidlin
Feb 3, 2005·Nature Reviews. Molecular Cell Biology·Carl P Blobel
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppArnab Chakravarti
Nov 3, 2007·Genes & Development·Frank B FurnariWebster K Cavenee
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Oct 24, 2008·The New England Journal of Medicine·Wells A Messersmith, Dennis J Ahnen
Sep 10, 2009·Science Signaling·Paul H HuangForest M White
May 7, 2010·CA: a Cancer Journal for Clinicians·Erwin G Van MeirJeffrey J Olson
Jun 17, 2010·Nature Reviews. Clinical Oncology·Deric L WheelerPaul M Harari
Sep 30, 2010·Cancer Investigation·Mark KatakowskiMichael Chopp
Oct 23, 2010·Nature Reviews. Cancer·William Pao, Juliann Chmielecki
Feb 10, 2011·CA: a Cancer Journal for Clinicians·Suresh S RamalingamFadlo R Khuri
Apr 5, 2012·The American Journal of Surgical Pathology·Jonathan HobbsCraig Horbinski
Jul 24, 2012·Cancer Treatment Reviews·Zuzana TatarXavier Durando
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kadoaki OhashiWilliam Pao
Mar 19, 2013·Trends in Immunology·Mario Leonardo SquadritoMikael J Pittet
May 7, 2013·Cancer Chemotherapy and Pharmacology·Jie WangZhong-ping Chen
Aug 14, 2013·Annual Review of Pathology·Timothy F CloughesyPaul S Mischel
Nov 1, 2013·Nature Reviews. Drug Discovery·Hui LingGeorge A Calin
Nov 7, 2013·JAMA : the Journal of the American Medical Association·Antonio Omuro, Lisa M DeAngelis
Nov 10, 2013·Nature Medicine·Curtis R Chong, Pasi A Jänne
Apr 24, 2014·International Journal of Oncology·Fei LuChunyan Ji
Aug 26, 2014·BMC Cancer·Yan-chang SunZhong-ping Chen
Sep 16, 2014·Advanced Drug Delivery Reviews·Guofeng Cheng
Oct 25, 2014·Neuro-oncology·Cecile L Maire, Keith L Ligon
May 7, 2015·Acta Neuropathologica·Kenneth AldapeAndreas von Deimling
May 17, 2015·Advanced Drug Delivery Reviews·Scott M Hammond
Jan 20, 2016·Nature Reviews. Neurology·Patrick Y Wen, David A Reardon

❮ Previous
Next ❯

Citations

Nov 20, 2019·Expert Opinion on Drug Discovery·Kenneth K W ToWilliam C S Cho
Jun 8, 2018·Journal of Neuro-oncology·Yaomin LiSongtao Qi
May 31, 2019·Journal of Experimental & Clinical Cancer Research : CR·George E D PetrescuMihnea P Dragomir
Sep 6, 2018·Neuromolecular Medicine·Wanli YuChunzhi Zhang
Jan 16, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Anna M Krichevsky, Erik J Uhlmann
Feb 18, 2020·Molecular Cancer·Jikui SunJinhuan Wang
Dec 20, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Bin XuJunfei Shao
Nov 11, 2019·Molecular Aspects of Medicine·Cornelia BraicuIoana Berindan-Neagoe
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiyue ZhangBin Feng
Oct 4, 2020·Experimental and Molecular Pathology·Omidvar RezaeiSoudeh Ghafouri-Fard
Nov 21, 2021·BMC Cancer·Lucy Wanjiku MachariaVivaldo Moura-Neto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Brain Lower Grade Glioma

Low grade gliomas in the brain form from oligodendrocytes and astrocytes and are the slowest-growing glioma in adults. Discover the latest research on these brain tumors here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.